Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences (NASDAQ: PCRX) presented two propensity score–matched real-world studies at ORS 2026 showing EXPAREL (liposomal bupivacaine) was associated with lower total cost of care versus ropivacaine and versus non-LB analgesia in TKA and spinal fusion. Reported benefits included lower 30-day total costs, reduced select resource use, and a shorter hospital length of stay in spinal fusion.
Summary not available.
Pacira BioSciences (Nasdaq: PCRX) responded to DOMA's nomination of three director candidates and reaffirmed its 5x30 strategy to drive long-term shareholder value. Key 2025 results: 2.5 million patients treated, EXPAREL volume +6.2% YoY, GAAP gross margin 79% (non-GAAP 81%), and $150 million share repurchases reducing shares from 47 to 41 million. The company highlighted expansion of its EXPAREL patent estate to 21 Orange-Book listed patents, progress in Phase 2 programs PCRX-201 and PCRX-2002, and several 2026 clinical milestones including a Phase 3 interim analysis and multiple topline readouts.
Summary not available.
Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards on March 3, 2026 to three new employees under its Amended and Restated 2014 Inducement Plan as permitted by Nasdaq Listing Rule 5635(c)(4).
One hire received options for 2,400 shares (10-year term, $22.10 exercise price, four-year vesting). Three hires received 5,500 RSUs vesting annually over four years beginning March 1, 2027.
Pacira BioSciences (NASDAQ:PCRX) will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 2:30 PM ET in Miami. Live audio will stream on the company Events page and a replay will be available for two weeks.
Pacira BioSciences (NASDAQ: PCRX) presented real-world IGOR registry data at AAOS 2026 showing benefits for EXPAREL and ioveraº in knee procedures and osteoarthritis pain. For TKA, liposomal bupivacaine (LB, n=42) showed lower acute NRS pain (3.9 vs 4.9; P<0.001), lower BPI-SF at 3 months (2.6 vs 2.9; P=0.03), and shorter hospital stays (15.0 vs 20.6 hours; P=0.007). Cryoneurolysis (n=129) was associated with sustained pain and functional improvements through 12 months (P<0.01) versus typical 4–6 month relief from intra-articular agents.
Findings derive from a multicenter, prospective, observational registry (IGOR) and were presented March 2, 2026 at AAOS.
Pacira BioSciences (Nasdaq: PCRX) reported Q4 2025 revenue of $196.9M and full-year revenue of $726.4M, led by EXPAREL sales of $155.8M in Q4 and $575.1M for 2025.
GAAP net income was $1.6M in Q4 and $7.0M for 2025; adjusted EBITDA was $38.7M in Q4 and $186.5M for the year. The company repurchased 5.9M shares for $150M in 2025 and provided 2026 guidance including EXPAREL sales of $600–$620M.
Pacira (Nasdaq: PCRX) will report fourth-quarter and full-year 2025 financial results after U.S. market close on Thursday, February 26, 2026. A live conference call and webcast will follow at 4:30 p.m. ET.
Investors can pre-register for the call to receive dial-in details and a PIN; a live audio webcast will be available on the company’s Events page at investor.pacira.com. A replay of the webcast will be available on the website for approximately two weeks after the call.
Pacira (Nasdaq: PCRX) highlighted survey findings from Voices for Non-Opioid Choices showing early impacts of the NOPAIN Act after its Jan 1, 2025 effective date. The national ATU survey of nearly 750 facilities found 85% awareness, 52% increased non-opioid use steps, and reductions in opioid prescribing.
Respondents reported decreases in immediate post-surgical prescribing (83%) and at discharge (88%), plus perioperative and postoperative protocol changes (52% and 51%).